Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
"Cheezhou" refers to a drug-eluting balloon catheter system, specifically the Cheezhou® (Bingo) Coronary Drug-Eluting Balloon Catheter. This medical device delivers the antiproliferative drug paclitaxel to the vessel wall during angioplasty. Paclitaxel interferes with microtubule function, inhibiting vascular smooth muscle cell proliferation and intimal hyperplasia, thereby preventing restenosis. The balloon also utilizes iodixanol as an excipient to enhance drug stability and bioavailability. Developed and manufactured by Liaoning Yinyi Biological Technology Co., Ltd., the Cheezhou drug-eluting balloon is indicated for the treatment of coronary artery disease, particularly for dilation of stenosis in primary bifurcation coronary artery lesions. It was the first drug-eluting balloon catheter approved in China for coronary bifurcation lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cheezhou.